A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening

Purpose

The purpose of this study is to develop a dedicated MRI scan of the pancreas (MRP) to better detect pancreatic cancer in people who are at a high risk for pancreatic cancer.

Conditions

  • Pancreatic Cancer
  • Pancreas Cancer

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Two first-degree relatives with pancreas cancer, one being a first-degree relative to the individual - Pathogenic mutation in APC, BRCA1, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2, or TP53 and a first/second-degree relative with pancreas cancer - Pathogenic mutation in CDKN2A/p16, STK11, PRSS1, SPINK1/PST1, CTRC, CPA1, ATM, or BRCA2 - Meets surveillance age eligibility, which is typically age 50, or 10 years earlier than the youngest relative with pancreas cancer. For individuals with certain gene mutations, this can be earlier. All participants must be aged 21+ For this pilot MRP study, we will additionally apply the following Criteria: - Consents to follow-up contact - US residents - Completed MRI with MRCP with no actionable findings related to the pancreas (e.g. a pancreatic mass) - No metallic artifacts covering the pancreas on prior MRCP - Scheduled for endoscopic ultrasound - No new contraindications for MRI (e.g. new MR unsafe device) - No history of claustrophobia or use of anxiolytic on prior MRI - No history of abdominal surgery that may affect interpretation of either EUS or MR - No medical conditions that confers increased and/or unacceptable risk for anesthesia We will recruit surveillance participants who had at least one prior MRCP in the last 3 years. They must also undergo a same-day EUS procedure as part of their surveillance. Nearly all active cohort participants have had at least one recent MRCP and, on average, our Registry gastroenterologist Dr. Rolston performs EUS in ~260 surveillance participants per year. Accordingly, it is highly feasible to recruit more than 79 participants in the grant period, and recruitment is constrained by budget. - Documentation of Disease o No pathologic confirmation of disease is necessary - Definition of Disease N/A - Not Pregnant and Not Nursing - Required Organ Function N/A

Exclusion Criteria

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Participants at high risk for pancreas ductal adenocarcinoma Participants will be high-risk individuals enrolled in the Memorial Sloan Kettering Pancreatic Tumor Registry
  • Diagnostic Test: MRI
    Participants will undergo a single MRI of the abdomen without contrast
    Other names:
    • Magnetic Resonance CholangioPancreatography, MRP
  • Diagnostic Test: Endoscopic ultrasound
    EUS will be scheduled the same day or within 2 weeks prior to MRP
    Other names:
    • EUS

Recruiting Locations

Memorial Sloan Kettering Basking Ridge (Consent Only)
Basking Ridge, New Jersey 07920
Contact:
Richard Kinh Gian Do, MD, PhD
212-639-8591

Memorial Sloan Kettering Monmouth (Consent only)
Middletown, New Jersey 07748
Contact:
Richard Kinh Gian Do, MD, PhD
212-639-8591

Memorial Sloan Kettering Bergen (Consent Only)
Montvale, New Jersey 07645
Contact:
Richard Kinh Gian Do, MD, PhD
212-639-8591

Memorial Sloan Kettering Suffolk-Commack (Consent only)
Commack, New York 11725
Contact:
Richard Kinh Gian Do, MD, PhD
212-639-8591

Memorial Sloan Kettering Westchester (Consent only)
Harrison, New York 10604
Contact:
Richard Kinh Gian Do, MD, PhD
212-639-8591

Memorial Sloan Kettering Cancer Center (All Protocol Activites)
New York, New York 10065
Contact:
Richard Kinh Gian Do, MD, PhD
212-639-8591

Memorial Sloan Kettering Nassau (Consent Only)
Uniondale, New York 11553
Contact:
Richard Kinh Gian Do, MD, PhD
212-639-8591

More Details

Status
Recruiting
Sponsor
Memorial Sloan Kettering Cancer Center

Study Contact

Richard Kinh Gian Do, MD, PhD
212-639-8591
dok@mskcc.org